Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine phase III placebo-controlled study in COPD
2020-002086-34Phase 3Completed
- Sponsor
- Verona Pharma
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Ensifentrine with Placebo (2 arms). Primary endpoint: Average forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 12 hours post-dose at Week 12. Started Aug 2020; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2020-002086-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002086-34.